CAS: 185040-32-8; 4-(Methylamino)-2-(Methylthio)Pyrimidine-5-Carbaldehyde

相似化合物

76360-82-2 17759-30-7 185040-35-1

上下游产品

CAS号17759-30-7 (4-甲基氨基-2-甲烷磺酰基... | CAS号5909-24-0 4-氯-2-甲硫基嘧啶-5-羧酸乙酯 | CAS号76360-82-2 2-(甲硫基)-4-(甲氨基)... | CAS号74-89-5 氨基甲烷 | CAS号185039-37-6 N-[6-(2,6-二氯苯基)... | CAS号214983-04-7 Pyrido[2,3-d]py... | CAS号185039-48-9 6-(2,6-二氯苯基)-8-... | CAS号185039-46-7 6-(2,6-Dichloro... | CAS号185039-29-6 6-(2,6-二氯苯基)-8-... | CAS号449811-92-1 6-(2,4-二氟苯氧基)-8... | CAS号449811-01-2 Pamapimod

6-氨基-2-硫氧代-1,2-二氢嘧啶-5-羧酸乙酯置于manganese(Iv) Oxide,Lithium Aluminium Tetrahydride体系中,用 四氢呋喃,乙醇,氯仿 用作溶剂,化学反应 42.25H,反应生成4-甲胺基-2-甲硫基-5-醛基嘧啶
参考文献:开发放射性碘化嘧啶并吡啶酮衍生物作为用于单光子发射计算机断层扫描的激活 P38α 的靶向成像探针
标题:开发放射性碘化嘧啶并吡啶酮衍生物作为用于单光子发射计算机断层扫描的激活 P38α 的靶向成像探针
摘要:客观的 P38α 是丝裂原激活蛋白激酶超家族的成员,在多种哺乳动物细胞中普遍表达.活化的p38α会诱导对外部刺激的炎症反应,这表明活化p38α的非侵入性检测对于诊断炎症性疾病具有重要意义.为此,我们基于有效的 P38α 选择性抑制剂 R1487 设计了放射性标记化合物 [ 123 I]2-Ir 和 [ 123 I]4-Ir,用于单光子发射计算机断层扫描 (Spect).在本研究中,我们使用125 I 代替123 I 因为其更有用的放射化学性质,合成了 [ 125 I]2-Ir 和 [ 125 I]4-Ir,并评估了它们作为激活的 P38α 成像探针的有效性. 方法 [ 123 I]2-Ir和[ 123 I]4-Ir是通过在苯氧基环的2-或4-位引入123 I原子而设计的,保留了r1487的嘧啶并吡啶酮结构.我们通过 7 步过程合成了 2-Ir 和 4-Ir.使用 Adp-Glo™
Doi:10.1007/s12149-021-01669-6

专利信息

专利号:US-7897762-B2
优先权日:2006-09-14
标 题:Kinase inhibitors useful for the treatment of proliferative diseases
发明人：FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C
权利人:DECIPHERA PHARMACEUTICALS LLC
摘要:The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

专利号:US-8188113-B2
优先权日:2006-09-14
标 题 :Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
发明人：FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C
权利人:FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C; DECIPHERA PHARMACEUTICALS INC
摘要:The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.